Intravitreal triamcinolone acetonide in the management of exogenous bacterial endophthalmitis

To determine the effectiveness of intravitreal triamcinolone acetonide in the management of bacterial endophthalmitis.

Interventional case series.

This pilot case series included five patients (three patients after trauma and two patients after cataract surgery) with culture proven bacterial endophthalmitis. After 48 to 72 hours of the initial surgical procedure, 4 mg/0.1 ml of intravitreal triamcinolone acetonide was injected, after confirmation that the vitreous isolate was sensitive to the initially administered intravitreal antibiotics. All patients received oral ciprofloxacin 750 mg twice each day for seven days. The course of inflammation and the clinical outcome were noted.

In all the five cases, there was complete resolution of inflammation with favorable clinical outcome at the end of one month that was maintained at the end of three months.

Intravitreal triamcinolone acetonide could be a treatment option in the selected cases of bacterial endophthalmitis.